Revolutionizing Treatment for EGFR-Mutated NSCLC

Coral Olazagasti, MD University of Miami Health System

November 25, 2025

1. Medical professional analyzing lung cancer CT scan highlighting tumor with red laser pointer, illustrating cancer diagnosis and screening.
Copy Link Share

The treatment landscape of EGFR-mutated non-small cell lung cancer (NSCLC) has undergone a remarkable and rapid transformation over the past several decades, defining what many now recognize as a revolution in this molecularly driven subtype. Though once associated with limited therapeutic options and poor long-term outcomes, EGFR-mutated NSCLC has evolved into one of the most dynamic and treatable forms of lung cancer, driven by innovations across localized, unresectable stage III, and metastatic disease. 

These advances have been propelled by highly effective targeted therapies, refined patient selection strategies, and meaningful improvements in survival, reaffirming both the treatability of this disease and the optimism clinicians and researchers share about the future of EGFR-directed treatment.1-11 

This momentum was clearly on display at the 2025 European Society for Medical Oncology (ESMO) Congress in Paris, France, where EGFR-mutated NSCLC remained a central focus of scientific discussion. Two landmark studies presented at the meeting, LAURA and OptiTROP-Lung 04, captured significant attention and underscored the evolving standards of care in both unresectable stage III disease and the post-EGFR tyrosine kinase inhibitor (TKI) metastatic setting. Data from both studies highlight the unprecedented progress and continued refinement of therapeutic strategies in this patient population.

The LAURA Study

The first major update came from the much-anticipated LAURA study, presented by Suresh Ramalingam, MD, FACP, FASCO, of the Winship Cancer Institute of Emory University. LAURA is a phase III, randomized, double-blind trial evaluating osimertinib as consolidation therapy in patients with unresectable stage III EGFR-mutated NSCLC who had not experienced disease progression following definitive concurrent chemoradiotherapy (CRT). The study enrolled 216 participants, randomized 2:1 to receive osimertinib or placebo. 

LAURA had previously met its primary endpoint, demonstrating a highly significant improvement in progression-free survival (PFS), establishing osimertinib as the first effective targeted therapy in this setting. Dr. Ramalingam presented the updated overall survival (OS) analysis at ESMO 2025. In this new update, the median OS was 58.8 months in the osimertinib arm compared with 54.0 months in the placebo arm, with a hazard ratio of 0.68 (95% CI, 0.40–1.14; P = 0.140). Although the analysis did not reach statistical significance for OS, the separation of the survival curves favors osimertinib, and the 48-month OS rates, 70% vs 52%, respectively, highlight a clinically meaningful benefit. 

Updated PFS data further showed a median of 48.2 months vs 47.4 months (HR 0.51; 95% CI, 0.28–0.91; P = 0.022), reinforcing the profound disease control achieved with osimertinib. Despite the lack of formal OS significance thus far, the ongoing positive trend and robust PFS benefit continue to support osimertinib as the clear standard of care for patients with unresectable stage III EGFR-mutated NSCLC following CRT. 

Continued long-term follow-up will be essential to determine whether the OS trend ultimately reaches statistical significance. Still, the clinical community widely agrees that osimertinib has reshaped the management of this population and established a new paradigm for consolidative treatment.12

OptiTROP-Lung 04

The second major update presented at ESMO 2025 was the OptiTROP-Lung 04 study, delivered by Dr. Zhang and simultaneously published in The New England Journal of Medicine. This pivotal phase III trial evaluated sacituzumab-TMT (SAC-TMT), a novel antibody-drug conjugate (ADC), in patients with metastatic EGFR-mutated NSCLC who had progressed after first-line EGFR-TKI therapy. The study randomized patients 1:1 to receive SAC-TMT or standard platinum–pemetrexed chemotherapy. 

The primary endpoint was PFS, with OS as a key secondary endpoint. The results demonstrated a compelling benefit for SAC-TMT across multiple efficacy outcomes. The median PFS was 8.3 months with SAC-TMT versus 4.3 months with chemotherapy (HR 0.49; P < 0.0001), and the 12-month PFS rates were 32% and 7.9%, respectively, an impressive and clinically meaningful separation. 

At the time of interim OS analysis, the median OS had not been reached in the SAC-TMT arm, compared with 17.4 months in the chemotherapy arm (HR 0.60; P = 0.001), suggesting a promising survival advantage. The median duration of response was also longer with SAC-TMT at 8.3 months versus 4.2 months, reflecting durable disease control in a setting where post-TKI options have historically been limited. 

Safety, a common concern with ADCs, was manageable, with stomatitis (64%) and ocular toxicity (9.6%) being the most notable adverse events, predominantly grade 1–2. Importantly, no cases of interstitial lung disease or pneumonitis were reported in either arm, an encouraging finding given the risk profiles observed with other ADCs.

Final Thoughts

These two studies presented at ESMO 2025 reinforce the rapidly evolving therapeutic landscape for EGFR-mutated NSCLC and position SAC-TMT as a potential new standard of care for patients who progress following first-line EGFR-TKI therapy. When paired with the consolidative role of Osimertinib in unresectable stage III disease, the EGFR field is now entering an era with multiple effective options across the disease continuum. 

As excitement grows, a key emerging question remains: how should we optimally sequence these therapies to maximize long-term survival? That discussion, however, is one for another day as the revolution in EGFR-mutated NSCLC continues to unfold.

References

  1. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. The New England Journal of Medicine. 2020;382(1):41-50. doi:10.1056/NEJMoa1913662.
  2. Cheng Y, He Y, Li W, et al. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, a Randomized Study. Targeted Oncology. 2021;16(2):165-176. doi:10.1007/s11523-021-00794-6.
  3. Gray JE, Ahn MJ, Oxnard GR, et al. Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis From AURA3 and FLAURA. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 2023;29(17):3340-3351. doi:10.1158/1078-0432.CCR-22-3146.
  4. Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. The New England Journal of Medicine. 2023;389(21):1935-1948. doi:10.1056/NEJMoa2306434.
  5. Jänne PA, Planchard D, Kobayashi K, et al. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC. The New England Journal of Medicine. 2025;. doi:10.1056/NEJMoa2510308.
  6. Tsuboi M, Herbst RS, John T, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. The New England Journal of Medicine. 2023;389(2):137-147. doi:10.1056/NEJMoa2304594.
  7. Wu YL, John T, Grohe C, et al. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. 2022;17(3):423-433. doi:10.1016/j.jtho.2021.10.014.
  8. Wu YL, Herbst RS, Mann H, et al. ADAURA: Phase III, Double-Blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-Positive Early-Stage NSCLC After Complete Surgical Resection. Clinical Lung Cancer. 2018;19(4):e533-e536. doi:10.1016/j.cllc.2018.04.004.
  9. Cho BC, Felip E, Hayashi H, et al. MARIPOSA: Phase 3 Study of First-Line Amivantamab + lazertinib Versus Osimertinib in EGFR-mutant Non-Small-Cell Lung Cancer. Future Oncology (London, England). 2022;18(6):639-647. doi:10.2217/fon-2021-0923.
  10. Hasan N, Nagasaka M. Amivantamab Plus Lazertinib vs. Osimertinib in First-Line EGFR-mutant Advanced Non-Small Cell Lung Cancer. Expert Review of Respiratory Medicine. 2025;:1-10. doi:10.1080/17476348.2025.2467338.
  11. Landre T, Assié JB, Chouahnia K, et al. First-Line Concomitant EGFR-TKI + Chemotherapy Versus EGFR-TKI Alone for Advanced EGFR-mutated NSCLC: A Meta-Analysis of Randomized Phase III Trials. Expert Review of Anticancer Therapy. 2024;24(8):775-780. doi:10.1080/14737140.2024.2362889.
  12. Ramalingam S, Özgüroglu M, Ahn M, et al. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): updated overall survival (OS) analysis from the LAURA study. Abstract #LBA4 presented at: European Lung Cancer Congress 2025, March 26-29; Paris, France.
  13. Wenfeng Fang, M.D., Lin Wu, Ph.D., Xiangjiao Meng, M.D. et al.  Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC. NEJM. October 19, 2025 DOI: 10.1056/NEJMoa2512071